☆ 4.4 Article

Introducing a simple and cost-effective RT-PCR protocol for detection of DPYD*2A polymorphism: the first study in Kurdish population

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

P. Garcia-Alfonso et al.

Summary: Genotyping DPYD gene polymorphisms before administering fluoropyrimidines can help classify individuals as normal, intermediate, or poor metabolizers, allowing for personalized treatment strategies to avoid toxicities. The consensus aims to provide clear recommendations for implementing genotype and/or phenotype testing for DPD deficiency in cancer patients receiving fluoropyrimidines.

CLINICAL & TRANSLATIONAL ONCOLOGY (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What are the Options?

Jonathan E. Knikman et al.

Summary: Fluoropyrimidines are widely used in the treatment of solid tumors, but severe toxicity can occur in a significant percentage of patients. Individualized dosing strategies, including upfront genotyping of the DPYD gene, monitoring of DPD enzyme activity, and pharmacokinetically guided follow-up of 5-FU, have shown promise in reducing toxicity. Baseline characteristics such as sex, age, body composition, and renal function also play a role in predicting severe toxicity and should be considered in dose-individualization strategies.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Pharmacogenetic profiling of dihydropyrimidine dehydrogenase (DPYD) variants in the Indian population

Shaik Mohammad Naushad et al.

Summary: The study identified four Level 1A (non-functional/dysfunctional) and seven Level 3 variants in the DPYD gene in the Indian population, with some variants associated with 5-FU/capecitabine toxicity. Clustering analysis revealed similarities in DPYD profiles of the Indian and South Asian populations.

JOURNAL OF GENE MEDICINE (2021)

添加到收藏夹

Article Oncology

Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience

Catherine Jolivet et al.

Summary: Fluoropyrimidines are commonly used in chemotherapy for various cancers. This study demonstrates the feasibility of upfront genotyping for DPYD before fluoropyrimidine-based treatment in clinical practice, which can help prevent severe toxicities without delaying treatment initiation. This approach of administering chemotherapy at reduced doses appears to be safe for patients with DPYD*2A mutations.

ONCOLOGIST (2021)

添加到收藏夹

Article Biology

Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing

Mourad A. M. Aboul-Soud et al.

Summary: Pharmacogenomics plays a crucial role in customizing therapy based on individual genetic makeup for cancer patients. Variations in drug metabolizing enzymes and associated transporter genes can significantly impact treatment outcomes by reducing drug efficacy and causing severe toxicities.

SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2021)

添加到收藏夹

Article Oncology

Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population

Jatta Saarenheimo et al.

Summary: This study describes the application of upfront DPD screening in Finnish patients, revealing that 8% of patients carried pathogenic DPYD variants causing DPD deficiency, including a novel intragenic deletion. The high prevalence of exon 4 deletion among Finnish patients emphasizes the importance of full-scale DPYD gene analysis and the use of genotype preemptive screening to detect DPD-deficient patients before fluoropyrimidine therapy.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events

Theodore J. Wigle et al.

Summary: Consensus guidelines for genotype-guided fluoropyrimidine dosing based on DPYD variation exist, but have not been widely implemented in North America. A study in a Canadian context found that DPYD variant carriers treated with genotype-guided dosing did not experience an increased risk for severe AEs. These findings support a role for DPYD genotyping in the use of fluoropyrimidines in North America.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)

添加到收藏夹

Review Oncology

Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis

Bhavina B. Sharma et al.

Summary: This study systematically evaluated the risk of treatment-related death associated with DPYD gene variants during fluoropyrimidine chemotherapy, and found that patients with pathogenic DPYD gene variants have a significantly increased risk of treatment-related death.

ONCOLOGIST (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study

Stephanie Detailleur et al.

Summary: The study investigated the frequencies of DPYD gene mutations and their correlation with toxicity grade in a Belgian population, finding DPYD*9A to be the most prevalent mutation. The suggestion was made to expand the screening for dihydropyrimidine dehydrogenase deficiency across multiple exons of the DPYD gene.

ANNALS OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines

Carin A. T. C. Lunenburg et al.

EUROPEAN JOURNAL OF HUMAN GENETICS (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future

Sona Vodenkova et al.

PHARMACOLOGY & THERAPEUTICS (2020)

添加到收藏夹

Article Oncology

Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients

Reza Negarandeh et al.

BMC CANCER (2020)

添加到收藏夹

Article Oncology

A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency

Nicolas Pallet et al.

BRITISH JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma

E. Puerta-Garcia et al.

SURGICAL ONCOLOGY-OXFORD (2020)

添加到收藏夹

Article Chemistry, Medicinal

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure

Marine Dolat et al.

PHARMACEUTICALS (2020)

添加到收藏夹

Article Oncology

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study

Francesco Iachetta et al.

BRITISH JOURNAL OF CANCER (2019)

添加到收藏夹

Article Genetics & Heredity

DPYD6 plays an important role in fluoropyrimidine toxicity in addition to DPYD2A and c.2846A>T: a comprehensive analysis in 1254 patients

Marzia Del Re et al.

PHARMACOGENOMICS JOURNAL (2019)

添加到收藏夹

Article Oncology

The Prevalence of DPYD*9A (c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis

Anu Singh Maharjan et al.

CLINICAL COLORECTAL CANCER (2019)

添加到收藏夹

Article Oncology

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis

Linda M. Henricks et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

添加到收藏夹

Article Health Care Sciences & Services

DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients

Arsalan Amirfallah et al.

JOURNAL OF PERSONALIZED MEDICINE (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Ursula Amstutz et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)

添加到收藏夹

Article Oncology

DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer

Noor Ahmed Nahid et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population

T. Elraiyah et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

添加到收藏夹

Article Oncology

Hydrogel microarray for detection of polymorphisms in the UGT1A1, DPYD, GSTP1 and ABCB1 genes

Rustam Heydarov et al.

CANCER BIOMARKERS (2017)

添加到收藏夹

Review Oncology

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update

L. M. Henricks et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients

A. Ruzzo et al.

BRITISH JOURNAL OF CANCER (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity

Q. Nie et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

添加到收藏夹

Article Oncology

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity

Didier Meulendijks et al.

BRITISH JOURNAL OF CANCER (2017)

添加到收藏夹

Review Oncology

Therapeutic drug monitoring of 5-fluorouracil

James J. Lee et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)

添加到收藏夹

Article Oncology

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

Maarten J. Deenen et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data

Didier Meulendijks et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Pharmacology & Pharmacy

Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score

Linda M. Henricks et al.

PHARMACOGENOMICS (2015)

添加到收藏夹

Article Medicine, General & Internal

Screening of Dihydropyrimidine Dehydrogenase Genetic Variants by Direct Sequencing in Different Ethnic Groups

Joong-Gon Shin et al.

JOURNAL OF KOREAN MEDICAL SCIENCE (2013)

添加到收藏夹

Article Pharmacology & Pharmacy

DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis

Salvatore Terrazzino et al.

PHARMACOGENOMICS (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.